161 related articles for article (PubMed ID: 36975820)
21. Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy.
Dominici LS; Mittendorf EA; Wang X; Liu J; Kuerer HM; Hunt KK; Brewster A; Babiera GV; Buchholz TA; Meric-Bernstam F; Bedrosian I
Breast Cancer Res; 2012 May; 14(3):R82. PubMed ID: 22621306
[TBL] [Abstract][Full Text] [Related]
22. Risk factors of recurrence in small-sized, node negative breast cancer in young women: a retrospective study in Chinese population.
Zhang X; Li P; Ma W; Di W; Zhao S; Gao Q; Zhao Y; Yang M; Zhang Q
Sci China Life Sci; 2013 Apr; 56(4):335-40. PubMed ID: 23483340
[TBL] [Abstract][Full Text] [Related]
23. Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.
Fan Y; Ding X; Xu B; Ma F; Yuan P; Wang J; Zhang P; Li Q; Luo Y
Medicine (Baltimore); 2015 Nov; 94(46):e2066. PubMed ID: 26579819
[TBL] [Abstract][Full Text] [Related]
24. Association between Parenchymal Enhancement of the Contralateral Breast in Dynamic Contrast-enhanced MR Imaging and Outcome of Patients with Unilateral Invasive Breast Cancer.
van der Velden BH; Dmitriev I; Loo CE; Pijnappel RM; Gilhuijs KG
Radiology; 2015 Sep; 276(3):675-85. PubMed ID: 25811614
[TBL] [Abstract][Full Text] [Related]
25. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
27. Improved overall survival over recent decades in patients with hormone-receptor-positive, HER2-negative breast cancer: a single-center retrospective analysis of prognostic factors.
Yamada Y; Mukai H; Tokudome Y; Kaneko M; Kashiwabara K; Wada N
Jpn J Clin Oncol; 2018 Mar; 48(3):248-254. PubMed ID: 29385493
[TBL] [Abstract][Full Text] [Related]
28. The clinical usefulness of the CTS5 in the prediction of late distant recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.
Tajiri W; Ijichi H; Takizawa K; Koi Y; Masuda T; Ueo H; Koga C; Nakamura Y; Taguchi K; Okamoto M; Tokunaga E
Breast Cancer; 2021 Jan; 28(1):67-74. PubMed ID: 32601800
[TBL] [Abstract][Full Text] [Related]
29. Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptor-Positive Breast Cancer.
Carleton N; Zou J; Fang Y; Koscumb SE; Shah OS; Chen F; Beriwal S; Diego EJ; Brufsky AM; Oesterreich S; Shapiro SD; Ferris R; Emens LA; Tseng G; Marroquin OC; Lee AV; McAuliffe PF
JAMA Netw Open; 2021 Apr; 4(4):e216322. PubMed ID: 33856473
[TBL] [Abstract][Full Text] [Related]
30. Prognostic relevance of biological subtype overrides that of TNM staging in breast cancer: discordance between stage and biology.
Jung HA; Park YH; Kim M; Kim S; Chang WJ; Choi MK; Hong JY; Kim SW; Kil WH; Lee JE; Nam SJ; Ahn JS; Im YH
Tumour Biol; 2015 Feb; 36(2):1073-9. PubMed ID: 25326808
[TBL] [Abstract][Full Text] [Related]
31. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
[TBL] [Abstract][Full Text] [Related]
32. Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy.
Elder EA; Livasy CA; Donahue EE; Neelands B; Patrick A; Needham M; Sarantou T; Hadzikadic-Gusic L; Heeke AL; White RL
Ann Surg Oncol; 2022 Dec; 29(13):8060-8069. PubMed ID: 35980548
[TBL] [Abstract][Full Text] [Related]
33. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
34. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
[TBL] [Abstract][Full Text] [Related]
35. Disease recurrence and oncological outcome of patients treated surgically with curative intent for estrogen receptor positive, lymph node negative breast cancer.
Davey MG; Ryan ÉJ; McAnena PF; Boland MR; Barry MK; Sweeney KJ; Malone CM; McLaughlin RJ; Lowery AJ; Kerin MJ
Surg Oncol; 2021 Jun; 37():101531. PubMed ID: 33545657
[TBL] [Abstract][Full Text] [Related]
36. The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer.
Yariv O; Mutai R; Rotem O; Tsoref D; Korzets Y; Moore A; Shochat T; Yerushalmi R; Goldvaser H
Oncology; 2021; 99(11):713-721. PubMed ID: 34515186
[TBL] [Abstract][Full Text] [Related]
37. Background Parenchymal Enhancement at Postoperative Surveillance Breast MRI: Association with Future Second Breast Cancer Risk.
Lee SH; Jang MJ; Yoen H; Lee Y; Kim YS; Park AR; Ha SM; Kim SY; Chang JM; Cho N; Moon WK
Radiology; 2023 Jan; 306(1):90-99. PubMed ID: 36040335
[TBL] [Abstract][Full Text] [Related]
38. First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer.
Ettl J; Anders SI; Hapfelmeier A; Paepke S; Noske A; Weichert W; Klein E; Kiechle M
Arch Gynecol Obstet; 2020 Dec; 302(6):1461-1467. PubMed ID: 32902674
[TBL] [Abstract][Full Text] [Related]
39. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR).
Gampenrieder SP; Peer A; Weismann C; Meissnitzer M; Rinnerthaler G; Webhofer J; Westphal T; Riedmann M; Meissnitzer T; Egger H; Klaassen Federspiel F; Reitsamer R; Hauser-Kronberger C; Stering K; Hergan K; Mlineritsch B; Greil R
Breast Cancer Res; 2019 Jan; 21(1):19. PubMed ID: 30704493
[TBL] [Abstract][Full Text] [Related]
40. cMET and phospho-cMET protein levels in breast cancers and survival outcomes.
Raghav KP; Wang W; Liu S; Chavez-MacGregor M; Meng X; Hortobagyi GN; Mills GB; Meric-Bernstam F; Blumenschein GR; Gonzalez-Angulo AM
Clin Cancer Res; 2012 Apr; 18(8):2269-77. PubMed ID: 22374333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
